Insight Molecular Diagnostics
IMDX
37 hedge funds and large institutions have $33.3M invested in Insight Molecular Diagnostics in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 5 closing their positions.
61% more capital invested
Capital invested by funds: $20.7M → $33.3M (+$12.6M)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
0.04% more ownership
Funds ownership: 0.66% → 0.7% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 41 → 37 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$2.83M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$131K |
| 3 |
Morgan Stanley
New York
|
+$19.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$16.7K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$8.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$218K |
| 2 |
Citigroup
New York
|
-$51K |
| 3 |
BlackRock
New York
|
-$40.5K |
| 4 |
FM
Family Management
New York
|
-$10.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.81K |
IMDX Hedge Fund Activity: Q3 2017 in Review
37 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2017, worth a combined $33.3M — up 61% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMDX and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was Broadwood Capital, adding an estimated $2.83M. The largest seller was Goldman Sachs, exiting entirely with an estimated $218K sold.
- 37 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2017, down from 41 in Q2 2017.
- Funds reported $33.3M of Insight Molecular Diagnostics stock for Q3 2017, up 61% quarter-over-quarter.
- 1 fund opened new Insight Molecular Diagnostics positions in Q3 2017 and 5 closed out, a net change of -4 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2017 was Broadwood Capital, an estimated $2.83M added.
- The largest Insight Molecular Diagnostics seller in Q3 2017 was Goldman Sachs, an estimated $218K sold.
Based on aggregated 13F filings for Q3 2017.